hotspot -WSS

hotspot

author：entertainment 2025-09-06 04:30:21 - browse：8

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Color Health wants to make cancer screenings convenient

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Adopting new red light myopia treatments may be short

Using force crossed my mind when examining a defiant young patient

Virtual repurposing can help discover new uses for existing drugs

Global cancer cases to surge 77% by 2050, WHO report says

Cholera vaccine supplies dangerously low, outbreaks surging

focus

hotspot

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

CDC panel: People 65 and older should get a Covid spring booster shot

Hepatitis C has a cure — but many Americans still lack access to it

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Problems with a popular proposal to regulate AI in health care

Jerome Adams on the need for new antivirals for Covid

STAT Madness 2024: Meet the contenders

Guidelines to prevent youth baseball injuries need more muscle

Children’s Hospital revives plan for pedestrian bridge

knowledge

The CDC's new social media misinformation war

AstraZeneca stays mum on Medicare drug pricing negotiations

Devoted Health’s losses in Medicare Advantage persist

Are embryos people? Reproductive medicine's future depends on the answer

Laying a path for careers in science

Virtual repurposing can help discover new uses for existing drugs

Wikipedia

hotspot

explore

hotspot